---
document_datetime: 2025-03-26 11:18:17
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/takhzyro-epar-all-authorised-presentations_en.pdf
document_name: takhzyro-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.7053871
conversion_datetime: 2025-12-29 21:47:43.416122
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## MA (EU) number (Invented) name Strength Pharmaceutical Form Route of Administration Immediate Packaging Content (concentration) Pack size

| EU/1/18/1340/001   | TAKHZYRO   | 300 mg   | Solution for injection   | Subcutaneous use   | vial (glass)                                  | 2 ml (150 mg/ml)   | 1 vial + 1 syringe + 2 needles                                        |
|--------------------|------------|----------|--------------------------|--------------------|-----------------------------------------------|--------------------|-----------------------------------------------------------------------|
| EU/1/18/1340/002   | TAKHZYRO   | 300 mg   | Solution for injection   | Subcutaneous use   | vial (glass)                                  | 2 ml (150 mg/ml)   | 2 (2 x 1) vials + 2 (2 x 1) syringes + 4 (2 x 2) needles              |
| EU/1/18/1340/003   | TAKHZYRO   | 300 mg   | Solution for injection   | Subcutaneous use   | vial (glass)                                  | 2 ml (150 mg/ml)   | 6 (6 x 1) vials + 6 (6 x 1) syringes + 12 (6 x 2) needles (multipack) |
| EU/1/18/1340/004   | TAKHZYRO   | 300 mg   | Solution for injection   | Subcutaneous use   | pre-filled syringe (glass)                    | 2 ml (150 mg/ml)   | 1 pre-filled syringe                                                  |
| EU/1/18/1340/005   | TAKHZYRO   | 300 mg   | Solution for injection   | Subcutaneous use   | pre-filled syringe (glass)                    | 2 ml (150 mg/ml)   | 2 pre-filled syringes                                                 |
| EU/1/18/1340/006   | TAKHZYRO   | 300 mg   | Solution for injection   | Subcutaneous use   | pre-filled syringe (glass)                    | 2 ml (150 mg/ml)   | 6 (3 x 2) pre-filled syringes (multipack)                             |
| EU/1/18/1340/007   | TAKHZYRO   | 150 mg   | Solution for injection   | Subcutaneous use   | pre-filled syringe (glass)                    | 1 ml (150 mg/ml)   | 1 pre-filled syringe                                                  |
| EU/1/18/1340/008   | TAKHZYRO   | 150 mg   | Solution for injection   | Subcutaneous use   | pre-filled syringe (glass)                    | 1 ml (150 mg/ml)   | 2 pre-filled syringes                                                 |
| EU/1/18/1340/009   | TAKHZYRO   | 150 mg   | Solution for injection   | Subcutaneous use   | pre-filled syringe (glass)                    | 1 ml (150 mg/ml)   | 6 (3 x 2) pre-filled syringes (multipack)                             |
| EU/1/18/1340/010   | TAKHZYRO   | 300 mg   | Solution for injection   | Subcutaneous use   | pre-filled syringe (glass) in pre- filled pen | 2 ml (150 mg/ml)   | 1 pre-filled pen                                                      |
| EU/1/18/1340/011   | TAKHZYRO   | 300 mg   | Solution for injection   | Subcutaneous use   | pre-filled syringe (glass) in pre- filled pen | 2 ml (150 mg/ml)   | 2 pre-filled pens                                                     |
| EU/1/18/1340/012   | TAKHZYRO   | 300 mg   | Solution for injection   | Subcutaneous use   | pre-filled syringe (glass) in pre- filled pen | 2 ml (150 mg/ml)   | 6 (3 x 2) pre-filled pens (multipack)                                 |